sellWeak cluster of 5
Charles N York II sold $70k of DAWN
COO and CFO at Day One Biopharmaceuticals, Inc.. 6,065 shares at an average of $11.60, traded Feb 17, 2026, filed Feb 18, 2026.
Warning score
30Value
$70k
6,065 shares
Holdings after
312,025
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +8Trade size$70k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001655962-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 15, 2026 | MOption exercise Common Stock | +2,250 | - | - | 296,965 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Common Stock | +6,625 | - | - | 303,590 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Common Stock | +6,625 | - | - | 310,215 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Common Stock | +7,875 | - | - | 318,090 | Feb 18, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock | -6,065 | $11.60 | $70k | 312,025 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -2,250 | $0.00 | $0 | 6,750 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 46,375 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 72,875 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Stock Unit (RSU)derivative | -7,875 | $0.00 | $0 | 118,125 | Feb 18, 2026 |
Related signals
Other insiders at Day One Biopharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $179k 15,459 shares | -7% | |
| 30Weak | Day One Biopharmaceuticals, Inc. | Michael Vasconcelles Head of Research and Dev. | $32k 2,728 shares | -38% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $74k 6,395 shares | -8% | |
| 23Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $67k 5,814 shares | -9% | |
| 36Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $142k 15,894 shares | -8% | |
| 28Weak | Day One Biopharmaceuticals, Inc. | Charles N York II COO and CFO | $36k 4,062 shares | -1% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Adam Dubow Gen Counsel & Secretary | $39k 4,319 shares | -6% | |
| 21Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $33k 3,726 shares | -7% | |
| 35Weak | Day One Biopharmaceuticals, Inc. | Jeremy Bender CHIEF EXECUTIVE OFFICER | $109k 16,058 shares | -9% | |
| 20Weak | Day One Biopharmaceuticals, Inc. | Lauren Merendino Chief Commercial Officer | $25k 3,766 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.